[Skeletal scintigraphy for the observation of course and treatment of carcinoma of the prostate ].
Serial skeletal scintigraphy was carried out on 259 patients with carcinoma of the prostate; 5-10% developed bone metastases each year. Isotope uptake was measured in 79 patients receiving treatment; in 60.6% (48 patients) there was a reduction or disappearance of the areas of uptake, in 16.6% (13 patients) they were stationary and 22.8% (18 patients) the metastases progressed. Skeletal scintigraphy is therefore useful during the course of the disease in showing its extent and the effect of treatment.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D002369:Castration; D011756:Diphosphates; D004164:Diphosphonates; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D011877:Radionuclide Imaging; D013667:Technetium; D017556:Technetium Compounds; D016698:Technetium Tc 99m Pyrophosphate
D000970:Antineoplastic Agents; D011756:Diphosphates; D004164:Diphosphonates; D004967:Estrogens; D017556:Technetium Compounds; D016698:Technetium Tc 99m Pyrophosphate; D013667:Technetium; C029045:technetium Tc 99m diphosphonate
Skelettszintigraphische Verlaufs- und Therapiekontrolle beim Prostatakarzinompatienten.